Overview

A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma

Status:
Completed
Trial end date:
2016-10-05
Target enrollment:
Participant gender:
Summary
This is a Phase I study combining vemurafenib and hydroxychloroquine in the treatment of BRAF V600E+ metastatic melanoma.
Phase:
Phase 1
Details
Lead Sponsor:
Abramson Cancer Center of the University of Pennsylvania
Treatments:
Hydroxychloroquine
Vemurafenib